FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076413986> ?p ?o ?g. }

• W2076413986 endingPage "584" @default.
• W2076413986 startingPage "584" @default.
• W2076413986 abstract "There are no treatments available to slow or prevent the progression of Parkinson disease, despite its global prevalence and significant health care burden. The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson Disease program was established to promote discovery of potential therapies.To determine whether creatine monohydrate was more effective than placebo in slowing long-term clinical decline in participants with Parkinson disease.The Long-term Study 1, a multicenter, double-blind, parallel-group, placebo-controlled, 1:1 randomized efficacy trial. Participants were recruited from 45 investigative sites in the United States and Canada and included 1741 men and women with early (within 5 years of diagnosis) and treated (receiving dopaminergic therapy) Parkinson disease. Participants were enrolled from March 2007 to May 2010 and followed up until September 2013.Participants were randomized to placebo or creatine (10 g/d) monohydrate for a minimum of 5 years (maximum follow-up, 8 years).The primary outcome measure was a difference in clinical decline from baseline to 5-year follow-up, compared between the 2 treatment groups using a global statistical test. Clinical status was defined by 5 outcome measures: Modified Rankin Scale, Symbol Digit Modalities Test, PDQ-39 Summary Index, Schwab and England Activities of Daily Living scale, and ambulatory capacity. All outcomes were coded such that higher scores indicated worse outcomes and were analyzed by a global statistical test. Higher summed ranks (range, 5-4775) indicate worse outcomes.The trial was terminated early for futility based on results of a planned interim analysis of participants enrolled at least 5 years prior to the date of the analysis (n = 955). The median follow-up time was 4 years. Of the 955 participants, the mean of the summed ranks for placebo was 2360 (95% CI, 2249-2470) and for creatine was 2414 (95% CI, 2304-2524). The global statistical test yielded t1865.8 = -0.75 (2-sided P = .45). There were no detectable differences (P < .01 to partially adjust for multiple comparisons) in adverse and serious adverse events by body system.Among patients with early and treated Parkinson disease, treatment with creatine monohydrate for at least 5 years, compared with placebo did not improve clinical outcomes. These findings do not support the use of creatine monohydrate in patients with Parkinson disease.clinicaltrials.gov Identifier: NCT00449865." @default.
• W2076413986 created "2016-06-24" @default.
• W2076413986 creator A5000092596 @default.
• W2076413986 creator A5001557633 @default.
• W2076413986 creator A5005169470 @default.
• W2076413986 creator A5008303763 @default.
• W2076413986 creator A5010932016 @default.
• W2076413986 creator A5011265761 @default.
• W2076413986 creator A5013990984 @default.
• W2076413986 creator A5016088619 @default.
• W2076413986 creator A5016152516 @default.
• W2076413986 creator A5017246900 @default.
• W2076413986 creator A5018934927 @default.
• W2076413986 creator A5019953946 @default.
• W2076413986 creator A5026567412 @default.
• W2076413986 creator A5026904802 @default.
• W2076413986 creator A5027520846 @default.
• W2076413986 creator A5028929566 @default.
• W2076413986 creator A5030208807 @default.
• W2076413986 creator A5030571101 @default.
• W2076413986 creator A5035628923 @default.
• W2076413986 creator A5036151807 @default.
• W2076413986 creator A5044416775 @default.
• W2076413986 creator A5045361289 @default.
• W2076413986 creator A5047486922 @default.
• W2076413986 creator A5049489643 @default.
• W2076413986 creator A5053232236 @default.
• W2076413986 creator A5054730708 @default.
• W2076413986 creator A5057376172 @default.
• W2076413986 creator A5058191272 @default.
• W2076413986 creator A5065433876 @default.
• W2076413986 creator A5070578599 @default.
• W2076413986 creator A5070950034 @default.
• W2076413986 creator A5071432943 @default.
• W2076413986 creator A5073744063 @default.
• W2076413986 creator A5074197949 @default.
• W2076413986 creator A5078787421 @default.
• W2076413986 creator A5080057970 @default.
• W2076413986 creator A5080273687 @default.
• W2076413986 creator A5083598511 @default.
• W2076413986 creator A5084458781 @default.
• W2076413986 creator A5087403478 @default.
• W2076413986 creator A5087563406 @default.
• W2076413986 creator A5088238884 @default.
• W2076413986 creator A5089160022 @default.
• W2076413986 date "2015-02-10" @default.
• W2076413986 modified "2023-10-17" @default.
• W2076413986 title "Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease" @default.
• W2076413986 cites W1561072761 @default.
• W2076413986 cites W1576177737 @default.
• W2076413986 cites W1969661146 @default.
• W2076413986 cites W1972991508 @default.
• W2076413986 cites W2022164794 @default.
• W2076413986 cites W2023687307 @default.
• W2076413986 cites W2031991866 @default.
• W2076413986 cites W2039650509 @default.
• W2076413986 cites W2041285652 @default.
• W2076413986 cites W2055308573 @default.
• W2076413986 cites W2088982973 @default.
• W2076413986 cites W2089085990 @default.
• W2076413986 cites W2092838550 @default.
• W2076413986 cites W2108901766 @default.
• W2076413986 cites W2128912109 @default.
• W2076413986 cites W2131987069 @default.
• W2076413986 cites W2136372119 @default.
• W2076413986 cites W2145337544 @default.
• W2076413986 cites W2147018298 @default.
• W2076413986 cites W2167924904 @default.
• W2076413986 cites W2170141518 @default.
• W2076413986 cites W2339005630 @default.
• W2076413986 cites W2358364508 @default.
• W2076413986 cites W2473786944 @default.
• W2076413986 cites W79347247 @default.
• W2076413986 doi "https://doi.org/10.1001/jama.2015.120" @default.
• W2076413986 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4349346" @default.
• W2076413986 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25668262" @default.
• W2076413986 hasPublicationYear "2015" @default.
• W2076413986 type Work @default.
• W2076413986 sameAs 2076413986 @default.
• W2076413986 citedByCount "184" @default.
• W2076413986 countsByYear W20764139862015 @default.
• W2076413986 countsByYear W20764139862016 @default.
• W2076413986 countsByYear W20764139862017 @default.
• W2076413986 countsByYear W20764139862018 @default.
• W2076413986 countsByYear W20764139862019 @default.
• W2076413986 countsByYear W20764139862020 @default.
• W2076413986 countsByYear W20764139862021 @default.
• W2076413986 countsByYear W20764139862022 @default.
• W2076413986 countsByYear W20764139862023 @default.
• W2076413986 crossrefType "journal-article" @default.
• W2076413986 hasAuthorship W2076413986A5000092596 @default.
• W2076413986 hasAuthorship W2076413986A5001557633 @default.
• W2076413986 hasAuthorship W2076413986A5005169470 @default.
• W2076413986 hasAuthorship W2076413986A5008303763 @default.
• W2076413986 hasAuthorship W2076413986A5010932016 @default.
• W2076413986 hasAuthorship W2076413986A5011265761 @default.
• W2076413986 hasAuthorship W2076413986A5013990984 @default.
• W2076413986 hasAuthorship W2076413986A5016088619 @default.

• next